Jacob Gottlieb and Stuart Weisbrod are titans in healthcare investing. They formerly worked together at Merlin BioMed Group. Now, it seems they are about to work together. Each one has been running a separate fund, but they are now under the same roof, meaning a partnership could be in the offing.
Weisbrod co-founded Merlin in 1998. It dealt with portfolios in pharmaceutical, medical devices and biotechnology among others. His career as in investor in the healthcare sector has been a success. He has previously worked with Merrill Lynch, Oracle Partners, and Prudential-Bache Securities where he dealt with biotechnology and healthcare investments.
Stuart Weisbrod is a Ph.D. holder in Biochemistry from the Princeton University. He also has an MBA from Columbia University and a BA from Colgate University.
Weisbrod created a team of professionals who would help him manage Merlin. Jacob Gottlieb is one of those picked to offer services. Gottlieb was assigned a role as a portfolio manager. Between 1999 and 2000, Gottlieb was at Merlin where he helped the fund to make returns of 100 percent during the biotechnology revolution.
Due to the success he had with funds management, Jacob Gottlieb got high-value clients some including family offices, endowment funds, pension funds and high net worth individuals. Merlin closed doors in 2007 after returning funds to its investors despite the success it had recorded.
After the closure of Merlin, Weisbrod created another form known as Iguana Healthcare Partners. The investment strategy is similar to Merlin. Jacob Gottlieb, on the other hand, created Visium Asset Management. The fund started with about $300 million as startup capital and quickly multiplied to $2.5 billion in one year. The fund serviced the 2008 global financial crisis and made even more profits that year closing the year at $8 billion.
Visium collapsed in 2016. Jacob Gottlieb worked for the fund for some time to return the funds to investors.
Now, these two successful investors are about to work together, meaning that the industry might very soon see some excitement coming from the two titans. The healthcare investment opportunities are likely to be sufficiently explored when the two form a joint force.